Research programme: restenosis therapeutics - KereosAlternative Names: KI-1004
Latest Information Update: 16 Jul 2016
At a glance
- Originator Kereos
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Coronary artery restenosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Coronary-artery-restenosis in USA
- 31 May 2010 Preclinical trials in Coronary artery restenosis in USA (unspecified route)